Wells Fargo
CGEM icon

Wells Fargo’s Cullinan Oncology CGEM Stock Holding History

Wells Fargo’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$933K Buy
51,256
+30,317
+145% +$450K ﹤0.01% 4157
2026
Q1 		$298K Sell
20,939
-39,575
-65% -$509K ﹤0.01% 4457
2025
Q4 		$626K Buy
60,514
+21,397
+55% +$193K ﹤0.01% 4320
2025
Q3 		$232K Buy
39,117
+6,378
+19% +$46.7K ﹤0.01% 4855
2025
Q2 		$247K Buy
32,739
+7,052
+27% +$56.7K ﹤0.01% 4648
2025
Q1 		$194K Buy
25,687
+823
+3% +$7.9K ﹤0.01% 4723
2024
Q4 		$303K Buy
24,864
+8,056
+48% +$116K ﹤0.01% 4518
2024
Q3 		$281K Buy
16,808
+2,916
+21% +$51.7K ﹤0.01% 4353
2024
Q2 		$242K Buy
13,892
+4,692
+51% +$99.9K ﹤0.01% 4389
2024
Q1 		$157K Buy
9,200
+1,173
+15% +$18.1K ﹤0.01% 4621
2023
Q4 		$81.8K Buy
8,027
+2,068
+35% +$18.3K ﹤0.01% 5027
2023
Q3 		$53.9K Sell
5,959
-3,119
-34% -$32.5K ﹤0.01% 5137
2023
Q2 		$97.7K Buy
9,078
+4,430
+95% +$47.1K ﹤0.01% 5056
2023
Q1 		$47.5K Buy
+4,648
New +$51.2K ﹤0.01% 5184
2022
Q4 		– Sell
-71
Closed -$1K – 7494
2022
Q3 		$1K Sell
71
-274
-79% -$3.69K ﹤0.01% 6298
2022
Q2 		$4K Sell
345
-10,742
-97% -$122K ﹤0.01% 6072
2022
Q1 		$116K Sell
11,087
-8,422
-43% -$114K ﹤0.01% 5246
2021
Q4 		$301K Buy
19,509
+19,453
+34,738% +$388K ﹤0.01% 5030
2021
Q3 		$1K Sell
56
-7,867
-99% -$210K ﹤0.01% 6669
2021
Q2 		$204K Buy
7,923
+3,828
+93% +$118K ﹤0.01% 5023
2021
Q1 		$171K Buy
+4,095
New +$166K ﹤0.01% 5228

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Wells Fargo's CGEM Position: Q2 2026 in Review

Wells Fargo increased its Cullinan Oncology (CGEM) stake by 145% in Q2 2026, buying an estimated $450K and bringing the position to 51,256 shares worth $933K. The position accounts for ﹤0.01% of the portfolio, ranked #4157.

Wells Fargo first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Wells Fargo held 51,256 shares of Cullinan Oncology worth $933K as of Q2 2026.
  • Wells Fargo bought 30,317 Cullinan Oncology shares in Q2 2026, an estimated $450K.
  • Cullinan Oncology made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4157 holding.
  • Wells Fargo first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.